クローン病を合併した残存小腸120cmの急性前骨髄球性白血病患者における経口トレチノイン(all-trans retinoic acid: ATRA)の体内動態

概要

論文の詳細を見る
Tretinoin (All-trans retinoic acid: ATRA) is the drug of choice for the remission induction treatment of acute promyelocytic leukemia (APL). Its action against APL cells involves the degradation of promyelocytic leukemia-retinoic acid receptor α (PML-RAR α) protein which represses their cellular differentiation. We treated a 44-year-old Japanese male patient with APL using orally administered ATRA. He had previously undergone multiple resections of the bowels due to Crohn's disease and his residual intestine length was only 120cm. In order to investigate the pharmacokinetics of ATRA in this patient, we measured the plasma concentrations. On the 11th day of orally administering ATRA twice a day, the maximum concentration (C_<max>) and the area under the plasma concentration versus time curve (AUC_<0-12>) of ATRA were 51.9μg/L and 460μg ・h/L, respectively. These data are comparable with those for patients without gastrointestinal complications, indicating that ATRA was sufficiently absorbed in spite of the patient having such a short intestine. Complete remission was achieved by the course of ATRA treatment.
日本医療薬学会の論文
2007-01-10